Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...

New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed ...

Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat ...

Eli Lilly has firmed up the label for its type 2 diabetes therapy Trulicity with FDA approval for a new cardiovascular risk reduction claim, as it faces increased competition from Novo Nordisk.

Lilly’s tirzepatide medicines face strong ... Among the growth products, Trulicity generated revenues worth $1.1 billion, down 25% year over year. Sales of Trulicity were in line with the ...

Lilly’s new products also contributed to sales growth. Trulicity sales continued to decline in the quarter. Despite the better-than-expected sales performance, Lilly’s shares were down almost ...

The decline was sharper after 2016, likely due to advancements in treatment options, greater uptake of precision medicine, ...

The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, ...